Related Experiment Video
Updated: May 19, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Genetic markers in oligodendroglial tumours
Tomaz Velnar1, Uros Smrdel, Mara Popovic
1Department of Neurosurgery, University Medical Centre Maribor, Maribor, Slovenia.
Radiology and Oncology
|August 31, 2012
Summary
Oligodendrogliomas, a type of glioma, show improved prognosis when exhibiting 1p and 19q loss. This genetic marker indicates better treatment sensitivity and aids in diagnosing brain tumors.
Area of Science:
- Neuro-oncology
- Cancer genetics
- Pathology
Background:
- Oligodendrogliomas are primary brain tumors originating from oligodendrocytes, representing a significant portion of glial tumors.
- These tumors constitute 2.5% of all primary brain tumors and 5-20% of all gliomas, highlighting their clinical relevance.
Purpose of the Study:
- To investigate the prognostic significance of 1p and 19q loss in oligodendroglial tumors.
- To evaluate the role of 1p and 19q loss as a predictive marker for treatment response and patient survival.
Main Methods:
- Analysis of genetic alterations, specifically 1p and 19q loss, in oligodendroglial tumor samples.
- Correlation of genetic findings with clinical behavior, treatment sensitivity, and patient outcomes.
Main Results:
- Oligodendroglial tumors with combined 1p and 19q loss exhibit a more indolent clinical course.
- These tumors demonstrate significantly higher sensitivity to chemotherapy and improved overall prognosis compared to tumors without this genetic alteration.
Conclusions:
- The 1p and 19q loss is a crucial biomarker for oligodendrogliomas, predicting a better prognosis.
- This genetic marker is clinically useful for assessing chemotherapy sensitivity, potentially improving diagnosis, and enhancing patient survival in oligodendroglioma management.
